Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main (gene editing) focus: Next-generation in vivo delivered gene-editing therapies
Company stage: Commercial
Diseases (gene editing): Genetic diseases of the liver, haemophilia, ophthalmology and autoimmune diseases
Genome editing tool: CRISPR-Cas9, Cas14 and Casɸ
Funding stage: Public (XETRA:BAYN.DE)
Location: Berlin, Germany
Gene editing partnerships: Mammoth Biosciences, Casebia Therapeutics
Bayer is a big pharma company with worldwide operations. The company is engaged in the gene-editing field by its joint venture firm, Casebia Therapeutics, which it launched together with CRISPR Therapeutics. The company also announced a collaboration with Mammoth Biosciences, where the two companies will utilise Mammoth's ultra-small Cas enzymes, Cas14 and Casɸ, for in vivo gene editing of multiple disease targets.